Reported AEs and potential risks are described in Section 7 . Appropriate dose modifica tions are described in Section 6 . No investigational or commercial agents or ther apies other than those described below may be administered with the intent to treat the patient’s malignancy. The patient will be requested to maintain a medication diary of each dose of medi cation. The medication diary will be returned to clinic staff at the end of each course.